Scinai Immunotherapeutics Ltd. (SCNI)
| Market Cap | 1.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.50M |
| Shares Out | 581.14K |
| EPS (ttm) | -4.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,609 |
| Open | 2.850 |
| Previous Close | 2.940 |
| Day's Range | 2.850 - 3.094 |
| 52-Week Range | 2.230 - 18.700 |
| Beta | 2.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 9, 2024 |
About SCNI
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax... [Read more]
News
Scinai Publishes Q1 2024 Financial Results and Provides Business Update
JERUSALEM , July 2, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I)...
Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.
JERUSALEM , June 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological prod...
Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement
JERUSALEM , June 7, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological prod...
Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance
JERUSALEM , May 24, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (the "Company") (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological p...
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update
JERUSALEM , May 15, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I)...
Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal
The Board has Approved a Ratio Change of the ADSs to Non-traded Ordinary Shares (equivalent to a reverse split) Designed to Regain Compliance JERUSALEM , May 6, 2024 /PRNewswire/ -- Scinai Immunothera...
Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
JERUSALEM , April 10, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on...
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
JERUSALEM , April 8, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that Ayana Pharma Ltd.
Scinai leadership to attend BIO-Europe Spring 2024
Showcasing Company's cGMP biologics CDMO and innovative NanoAb pipeline JERUSALEM , March 12, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on...
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
JERUSALEM , Feb. 29, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and pro...
Scinai Welcomes Liat Halpert as Head of Business Development and Sales
JERUSALEM , Feb. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and pro...
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize
JERUSALEM , Jan. 25, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, co...
Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
JERUSALEM , Jan. 4, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused both on development of inflammation and immunology (I&I) biological therapeu...
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
JERUSALEM , Jan. 4, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, tod...
Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
JERUSALEM , Dec. 29, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused both on development of inflammation and immunology (I&I) biological therape...
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9
JERUSALEM , Dec. 27, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused both on development of inflammation and immunology (I&I) biological product...
Scinai Announces Promising Results in a Psoriatic Human Skin Model
JERUSALEM , Dec. 12, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology biological products, is pleas...
Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug
Data backs use of Scinai's aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases, addressing significant medical needs JERUSALEM , Dec. 11, 2023 /PRNewswire/ -- Scina...
European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031
Significant positive impact to Scinai's financial health is expected Amendment made in light of Scinai's recent strategic shift to development of nanosized antibody therapeutics aimed at inflammation ...
Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule
JERUSALEM , Nov. 20, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced today the receipt of formal notification from the Nasdaq Stock Market ("Nasdaq") that the Compan...
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
JERUSALEM, Nov. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that the Israel Innovation Authority (IIA) has approved a non-dilutive grant cover...
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative i...
European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai's recent strategic pivot
JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative i...
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
Targeting biotech companies with drug production process development and optimization, analytical methods development, and GMP production for clinical trials Targeting biotech companies with drug prod...